Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19

By sjmartinez • January 21, 2023

Taiwo BO, Chew KW, Moser C, Wohl DA, Daar ES, Li JZ, Greninger AL, Bausch C, Luke T, Hoover K, Neytman G, Giganti MJ, Olefsky M, Javan AC, Fletcher CV, Eron JJ, Currier JS, Hughes MD, Smith DM; ACTIV-2/A5401 Study Team. Phase 2 safety and antiviral activity of SAB-185, a novel polyclonal antibody therapy for non-hospitalized adults with COVID-19. J Infect Dis. 2023 Jan 20:jiad013. doi: 10.1093/infdis/jiad013. Epub ahead of print. PMID: 36661240.

Tags: antibody, covid-19, Infectious Diseases, polyclonal, Publications, SAB-185, transchromosomic, Treatment

Advancing the inclusion of pregnant and lactating populations in HIV PrEP research: ethical, regulatory, and surveillance recommendations from a multisectoral working group

Osakwe CE, Schaefer R, Donaldson L, Abiodun AS, Chatani-Gada M, Chigome AK, Day S, Deaton C, Elemuwa UG, Ingold H, Joseph Davey D, Kersey K,[...]

A Community-Based Intervention to Increase PrEP Initiation and Reduce Internalized Stigma: A Randomized Trial Among Black Sexual Minority Men in Prince George’s County, Maryland

Turpin RE, Wilson GT, Davidson Mhonde RR, Camp AD, Dyer TV, Mayer KH, Liu H, Coates T, Boekeloo B. A Community-Based Intervention to Increase PrEP[...]

Altered bile acid metabolism in people with HIV correlates with systemic and intestinal inflammation

Irwin S, Elliott J, Li F, Ruiz P, Anton PA, Du X, Fulcher JA. Altered bile acid metabolism in people with HIV correlates with systemic[...]